The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.

This invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N-Acetylgalactosamine phosphoramidite molecules and to conjugates of nucleic acid molecules with N-Acetylgalactosamine containing molecules. Also provided are methods for preparation of these molecules and possible uses thereof, in particular in medicine.

This invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N-Acetylgalactosamine phosphoramidite molecules and to conjugates of nucleic acid molecules with N-Acetylgalactosamine containing molecules. Also provided are methods for preparation of these molecules and possible uses thereof, in particular in medicine.

The present invention discloses a glucose gemini surfactant compound comprising a dodecyl glucose gemini surfactant and tetradecyltrimethylammonium chloride, or a tetradecyl glucose gemini surfactant and cetyl trimethylammonium bromide; the present invention also discloses a process for the preparation of the glucose gemini surfactant compounds. The glucose gemini surfactant compounds of the invention have the high activity characteristic of the gemini surfactant and is suitable for the separation and extraction of the detergents and the biofilm protein, and are novel non-toxic or low toxic and biodegradable glycosyl gemini surfactants. The preparation method of the compound surfactants is simple and easy to be industrialized.

The invention relates to a method for producing a glycoconjugate comprising an oligosaccharide part covalently linked to a non-sugar moiety selected from the group consisting of amino acids, peptides, proteins, lipids, longer alkyl groups, polyethylene glycols, α,β-unsaturated amido group and polyvinyl alcohols, using a genetically modified cell.

The invention relates to a method for producing a glycoconjugate comprising an oligosaccharide part covalently linked to a non-sugar moiety selected from the group consisting of amino acids, peptides, proteins, lipids, longer alkyl groups, polyethylene glycols, α,β-unsaturated amido group and polyvinyl alcohols, using a genetically modified cell.

A tetrasaccharide of formula I and a method of production thereof are provided. Furthermore, a conjugate comprising the tetrasaccharide and a molecule attached to the tetrasaccharide, preferably via its amine group, is also provided. Compositions, preferably immunogenic or vaccine compositions, comprising this tetrasaccharide or this conjugate are also provided. Such tetrasaccharides, conjugates, and compositions can be used for preventing or treating a disease caused by a Burkholderia infection in a subject, for inducing the production of anti-Burkholderia antibodies in a subject, or for diagnosing a Burkholderia infection in a subject. Preferably, the Burkholderia infection is an infection by Burkholderia pseudomallei (Bp) or Burkholderiamallei (Bm); the disease is melioidosis or glander; and/or the anti-Burkholderia antibodies are anti-Burkholderia pseudomallei(Bp) antibodies or anti-Burkholderia mallei (Bm)

A tetrasaccharide of formula I and a method of production thereof are provided. Furthermore, a conjugate comprising the tetrasaccharide and a molecule attached to the tetrasaccharide, preferably via its amine group, is also provided. Compositions, preferably immunogenic or vaccine compositions, comprising this tetrasaccharide or this conjugate are also provided. Such tetrasaccharides, conjugates, and compositions can be used for preventing or treating a disease caused by a Burkholderia infection in a subject, for inducing the production of anti-Burkholderia antibodies in a subject, or for diagnosing a Burkholderia infection in a subject. Preferably, the Burkholderia infection is an infection by Burkholderia pseudomallei (Bp) or Burkholderiamallei (Bm); the disease is melioidosis or glander; and/or the anti-Burkholderia antibodies are anti-Burkholderia pseudomallei(Bp) antibodies or anti-Burkholderia mallei (Bm)

The present invention relates to a synthetic oligosaccharide of general formula (I): T*-[(—U.sub.x+4—U.sub.x+3—U.sub.x+2—U.sub.x+1—U.sub.x).sub.m—(V.sub.x+2—V.sub.x+1—V.sub.x).sub.1-m-T-O-L-E that is related to Klebsiella pneumoniae serotype O3, O3b and/or O5 lipopolysaccharide and conjugate thereof. Said synthetic oligosaccharide, said conjugate and pharmaceutical composition containing said synthetic oligosaccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Klebsiella pneumoniae. Furthermore, the synthetic oligosaccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Klebsiella pneumoniae serotype O3, O3b and/or O5 bacteria.

The present disclosure relates to analogs of N-acetyl glucosamine fluorinated at 4- and/or 6-position(s) and derivatives of xylose at anomeric position for the treatment of a neurological disease, inflammation, cancer and a central nervous system injury.